Cancer News and Research

Latest Cancer News and Research

Rice scientists develop new tool to analyze thermal behaviors of DNA and RNA strands

Rice University scientists have developed a tool to speed the design of molecular diagnostics that depend on the specific recognition of pathogen DNA and RNA.

20 Jan 2016

New method could improve accurate diagnosis of ovarian cancer before surgery

In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99% of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral and non-referral centers.

20 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

Common mortality causes prevail in epilepsy patients

A prospective, community-based study confirms that patients with epilepsy usually die of the same causes as other people.

19 Jan 2016

WASF3 protein appears to be solid target for reducing cancer metastasis

A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report.

19 Jan 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration is a condition of the macula, a tiny area of the retina at the back of the eye. Your macula is only about the size of the grain of rice, that’s about four millimeters across.

19 Jan 2016

Needle-free administration of anesthetic in the mouth could save costs, improve patient compliance

If you're scared of the dentist's needles you're not alone - but new research means you might not have to put off that appointment again. A study published in Colloids and Surfaces B: Biointerfaces reveals how the dentist could give you anesthetic using a tiny electric current instead of a needle.

19 Jan 2016

Phthalate DEHP could lead to weight gain

In cooperation with the Integrated Research and Treatment Center Adiposity Diseases at the University of Leipzig and the University Hospital Leipzig, researchers from the Helmholtz Centre for Environmental Research have now published a study in the PLOS ONE journal showing that the phthalate DEHP leads to weight gain and revealed the metabolic processes involved.

19 Jan 2016

Adaptive, light-activated nanotherapy effective against drug-resistant bacteria

In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.

19 Jan 2016

CRISPR/Cas9 gene editing technique could be controlled using RNA-based drugs

In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites.

19 Jan 2016

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

19 Jan 2016

Researchers suggest ways to make TB drugs more efficacious against mutations

Biophysicists have discovered why the bacteria that cause tuberculosis (TB) are naturally somewhat resistant to antibiotics known as fluoroquinolones. Their findings, based on mapping the detailed three-dimensional structure of the drugs interacting with an essential enzyme in the TB germ, also reveal why some TB drugs are more potent than others and suggest how drug developers can make fluoroquinolones more efficacious against mutations that make the lung disease drug resistant.

19 Jan 2016

New study finds that living in high-rise buildings may affect survival after cardiac arrest

The number of people living in high-rise buildings in rising, but along with the convenience and panoramic views of a downtown condo comes a risk: a new study found that survival rates from cardiac arrest decrease the higher up the building a person lives.

19 Jan 2016